Stem cell and cellular therapy developments

Michael Strong, Albert Farrugia, Paolo Rebulla

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recent discoveries on human and non-human stem cells have prompted the development of several studies aimed at the translation of laboratory evidences into novel clinical procedures collectively known as 'cellular therapy'. In this regard, a number of features specifically related to the clinical setting require stringent evaluation, including, but not limited to: ethical appropriateness; donor and recipient informed consent; autologous versus allogeneic use; media and devices for cell collection, processing, characterization, storage and distribution; donor and recipient adverse events registration and management; risk-to-benefit and cost analysis; outcome analysis; production sites accreditation and management; regulatory oversight. This article describes recent national and international developments related to the distribution of cells and tissues for clinical use. Moreover, an example is reported of the implementation of a cellular therapy production site compliant with good manufacturing practices (GMPs) in a large European University hospital.

Original languageEnglish
Pages (from-to)103-107
Number of pages5
JournalBiologicals
Volume37
Issue number2
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Cell- and Tissue-Based Therapy
Stem cells
Stem Cells
Accreditation
Tissue Distribution
Informed Consent
Cost-Benefit Analysis
Tissue
Costs and Cost Analysis
Equipment and Supplies
Therapeutics
Processing
Costs

Keywords

  • Cells
  • GMP
  • Tissue
  • Transplants

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Stem cell and cellular therapy developments. / Strong, Michael; Farrugia, Albert; Rebulla, Paolo.

In: Biologicals, Vol. 37, No. 2, 04.2009, p. 103-107.

Research output: Contribution to journalArticle

Strong, Michael ; Farrugia, Albert ; Rebulla, Paolo. / Stem cell and cellular therapy developments. In: Biologicals. 2009 ; Vol. 37, No. 2. pp. 103-107.
@article{51c47789271c4848bca173996f906ed8,
title = "Stem cell and cellular therapy developments",
abstract = "Recent discoveries on human and non-human stem cells have prompted the development of several studies aimed at the translation of laboratory evidences into novel clinical procedures collectively known as 'cellular therapy'. In this regard, a number of features specifically related to the clinical setting require stringent evaluation, including, but not limited to: ethical appropriateness; donor and recipient informed consent; autologous versus allogeneic use; media and devices for cell collection, processing, characterization, storage and distribution; donor and recipient adverse events registration and management; risk-to-benefit and cost analysis; outcome analysis; production sites accreditation and management; regulatory oversight. This article describes recent national and international developments related to the distribution of cells and tissues for clinical use. Moreover, an example is reported of the implementation of a cellular therapy production site compliant with good manufacturing practices (GMPs) in a large European University hospital.",
keywords = "Cells, GMP, Tissue, Transplants",
author = "Michael Strong and Albert Farrugia and Paolo Rebulla",
year = "2009",
month = "4",
doi = "10.1016/j.biologicals.2009.01.003",
language = "English",
volume = "37",
pages = "103--107",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Stem cell and cellular therapy developments

AU - Strong, Michael

AU - Farrugia, Albert

AU - Rebulla, Paolo

PY - 2009/4

Y1 - 2009/4

N2 - Recent discoveries on human and non-human stem cells have prompted the development of several studies aimed at the translation of laboratory evidences into novel clinical procedures collectively known as 'cellular therapy'. In this regard, a number of features specifically related to the clinical setting require stringent evaluation, including, but not limited to: ethical appropriateness; donor and recipient informed consent; autologous versus allogeneic use; media and devices for cell collection, processing, characterization, storage and distribution; donor and recipient adverse events registration and management; risk-to-benefit and cost analysis; outcome analysis; production sites accreditation and management; regulatory oversight. This article describes recent national and international developments related to the distribution of cells and tissues for clinical use. Moreover, an example is reported of the implementation of a cellular therapy production site compliant with good manufacturing practices (GMPs) in a large European University hospital.

AB - Recent discoveries on human and non-human stem cells have prompted the development of several studies aimed at the translation of laboratory evidences into novel clinical procedures collectively known as 'cellular therapy'. In this regard, a number of features specifically related to the clinical setting require stringent evaluation, including, but not limited to: ethical appropriateness; donor and recipient informed consent; autologous versus allogeneic use; media and devices for cell collection, processing, characterization, storage and distribution; donor and recipient adverse events registration and management; risk-to-benefit and cost analysis; outcome analysis; production sites accreditation and management; regulatory oversight. This article describes recent national and international developments related to the distribution of cells and tissues for clinical use. Moreover, an example is reported of the implementation of a cellular therapy production site compliant with good manufacturing practices (GMPs) in a large European University hospital.

KW - Cells

KW - GMP

KW - Tissue

KW - Transplants

UR - http://www.scopus.com/inward/record.url?scp=63249117610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249117610&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2009.01.003

DO - 10.1016/j.biologicals.2009.01.003

M3 - Article

VL - 37

SP - 103

EP - 107

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 2

ER -